South Korea's Ministry of Intellectual Property has issued a decision to grant a patent covering the method of reconstituting liposomal Annamycin, adding another major market to its patent estate spanning more than 20 jurisdictions.
MBRX · Moleculin Biotech, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 65%
- Last earnings
- May 14, 2025
- Latest filing
- 10-Q · Nov 13
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Moleculin Biotech, Inc. completed Part A treatment for all 90 patients in the Phase 2/3 MIRACLE trial, with comprehensive data on track for the first quarter of 2027. Third-quarter net loss was approximately $6.5 million.
Moleculin closed MIRACLE Part A enrollment at 90 subjects; data are expected in the first quarter of 2027, after interim complete remission rates of 43% and 36% in two Annamycin arms versus 12% for control.
Moleculin Biotech announced Australian Patent No. 2020303572, covering preparation of preliposomal Annamycin lyophilizate, granted to Moleculin and The Board of Regents of The University of Texas System, strengthening intellectual property protection for its investigational anthracycline Annamycin.
Moleculin Biotech said Annamycin (naxtarubicin) combined with PD-1 immune checkpoint blockade significantly increased survival in pancreatic cancer models versus either agent alone, with the result reconfirmed in a second experiment.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net cash used in operating activities | $21.7M | Nine months ended September 30, 2026 | — |
| Gross proceeds from shares sold pursuant to the 2025 ATM Agreement | $0.8M | the three months ended September 30, 2026 filing | — |
| Shares of common stock sold pursuant to the 2025 ATM Agreement | 69,969 | the three months ended September 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MBRX
this stock
Moleculin Biotech, Inc.
|
$8.22M | — | — | — | 5.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 60
South Korea's Ministry of Intellectual Property has issued a decision to grant a patent covering the method of reconstituting liposomal Annamycin, adding another major market to its patent estate spanning more than 20 jurisdictions.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MBRX | -1.7% | +19.1% | -85.3% | -2.0% | -88.3% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +6.9% | +28.3% | -76.2% | +6.7% | -89.5% |